Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

Figure 2

Relapse-free survival curves for patients classified by genetic characteristics. (A) Patients with gain of BIRC5 and those with a normal copy, loss, or UPD of BIRC5 in the tumors, (B) patients with gain of AIB1 and those with a normal copy or loss of AIB1 in the tumors, (C) 20 patients with HR+ or HR- tumors with combined aberrations of PIK3CA, PTEN, and INPP4B, and 22 patients with HR+ or HR- tumors with no aberrations of PIK3CA, PTEN, and INPP4B, (D) 13 patients with HR+ tumors with combined aberrations of PIK3CA, PTEN, and INPP4B, and 12 patients with HR+ tumors with no aberrations of PIK3CA, PTEN, and INPP4B, (E) 13 patients with HR+ or HR- tumors with combined aberrations of PIK3CA, PTEN, and INPP4B, and 21 patients with HR+ or HR- tumors with no aberrations of PIK3CA, PTEN, and INPP4B, and (F) 7 patients with HR+ tumors with combined aberrations of PIK3CA, PTEN, and INPP4B, and 12 patients with HR+ tumors with no aberrations of PIK3CA, PTEN, and INPP4B.

Back to article page
\